Mastectomy vs breast-conserving surgery: An old dilemma comes again for early breast cancer

Annals of Surgical Oncology

Volumn 17, Issue 7, 2010, Pages 1966-1967

  Harissis, H V ^a   Ziogas, D ^a   Baltogiannis, G ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; BREAST RECONSTRUCTION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; HUMAN; INTERMETHOD COMPARISON; LETTER; MASTECTOMY; TUMOR VOLUME; BREAST NEOPLASMS; COMPARATIVE STUDY; FEMALE; SEGMENTAL MASTECTOMY;

BREAST NEOPLASMS; FEMALE; HUMANS; MASTECTOMY; MASTECTOMY, SEGMENTAL;

EID: 77955681448     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-1103-3     Document Type: Letter

References (13)

1. Ziogas D, Roukos DH. Genetics and personal genomics for personalized breast cancer surgery: progress and systems biology. Ann Surg. 2009;249:1067-8.
2. Roukos DH. Radiation therapy for breast cancer. N Engl J Med. 2009;360:1362; author reply 1363.
3. McGuire, Santillan AA, Kaur P, Meade T, Parbhoo J, Mathias M, et al. Are mastectomies on the rise? A 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients. Ann Surg Oncol. 2009;16:2682-90.
4. Roukos DH. Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and challenges in research and clinical practice. Ann Surg Oncol. 2009;16:1771-82.
5. Roukos DH. Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn. 2009;9:217-21.
6. Roukos DH. Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn. 2010;10(3):247-50.
7. Roukos DH. Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. J Clin Oncol. 2010. doi:10.1200/JCO.2009.27.7061 [Epub ahead of print].
8. Roukos DH. Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 2010;11(3):283-7.
9. Roukos DH, Ziogas D. From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther. 2010;10(2):123-8.
10. Roukos DH. Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn. 2010;10(1):33-48.
11. Roukos DH. Isolated tumor cells in breast cancer. N Engl J Med. 2009;361:1994-5.
12. Roukos DH, Tzakos A, Zografos G. Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther. 2009;9(10):1413-6.
13. Roukos DH. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol. 2010;17:14-7.